



CS/NSE/PR/2014-2015
October 7, 2014

To
The Manager – Listing Department,
National Stock Exchange of India Ltd
"Exchange Plaza", Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051

Dear Sir/Madam,


Scrip Code – SUVEN-EQ

Sub: Press Release

.....
With reference to above subject, please find enclosed Press Release of our company titled
**"Suven Life Sciences is selected as one of the "Best Under A Billion" companies by
Forbes Asia 2014"**

This is for your information and records.

Thanking You,
Yours faithfully,
For SUVEN LIFE SCIENCES LIMITED


K HANUMANTHA RAO
Company Secretary

Suven Life Sciences Limited

CIN: L24110TG1989PLC009713

Registered Office: 8-2-334 I SDE Serene Chambers I 6th Floor I

Road No.5 I Avenue 7 I Banjara Hills I Hyderabad – 500 034 I Telangana I India

Tel: 91 40 2354 1142/ 3311/ 3315 Fax: 91 40 2354 1152 Email: info@suven.com website: www.suven.com



News Release

Suven Life Sciences is selected as one of the "Best Under A Billion" companies by Forbes Asia 2014.

HYDERABAD, INDIA (October 07, 2014) – Suven Life sciences Ltd (Suven) announces today that Suven is selected as one of the "Best Under A Billion" companies by Forbes Asia 2014.

Forbes Asia's "Best Under A Billion" list highlights 200 of the best small and mid-sized listed companies in Asia Pacific with annual revenue under \$1 billion. To qualify for the selection, companies must have revenue between \$5 million and \$1 billion, positive net income and be publicly traded for at least a year. From a universe of 17,000 companies, qualified candidates are screened on sales growth, earnings growth and return on equity. The result is a final list featuring 200 exceptional small and mid-sized companies from Asia Pacific.

In recognition of the achievement of these 200 "Best Under A Billion" Companies, Forbes Asia is organizing an Award Ceremony and Dinner and Suven will receive this award on 9th December 2014 in Bangkok, Thailand.

Suven Life Science is a biopharmaceutical company focused on discovering, developing and commercializing novel pharmaceutical products, which are first in class or best in class CNS therapies through the use of GPCR targets. **The Company has twelve (12) internally-discovered therapeutic drug candidates currently in pre-clinical stage of development targeting conditions such as ADHD, dementia, major depressive disorder (MDD), Huntington's disease, Parkinson's disease and obesity in addition to developmental candidate SUVN-502 for Alzheimer's disease and Schizophrenia.**

For more information please visit our Web site at <http://www.suven.com>

Risk Statement:

Except for historical information, all of the statements, expectations and assumptions, including expectations and assumptions, contained in this news release may be forward-looking statements that involve a number of risks and uncertainties. Although Suven attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause results to differ materially including outsourcing trends, economic conditions, dependence on collaborative partnership programs, retention of key personnel, technological advances and continued success in growth of sales that may make our products/services offerings less competitive; Suven may not undertake to update any forward-looking statements that may be made from time to time.

Suven Life Sciences Limited

CIN: L24110TG1989PLC009713

Registered Office: 8-2-334 I SDE Serene Chambers I 6th Floor I

Road No.5 I Avenue 7 I Banjara Hills I Hyderabad – 500 034 I Telangana I India

Tel: 91 40 2354 1142/ 3311/ 3315 Fax: 91 40 2354 1152 Email: info@suven.com website: www.suven.com